{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T13:50:52Z","timestamp":1762005052707,"version":"3.40.5"},"reference-count":28,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diagnostic Microbiology and Infectious Disease"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.diagmicrobio.2019.01.012","type":"journal-article","created":{"date-parts":[[2019,1,27]],"date-time":"2019-01-27T15:45:24Z","timestamp":1548603924000},"page":"297-303","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Evaluation of in vitro activity of ceftolozane-tazobactam compared to other antimicrobial agents against Pseudomonas aeruginosa isolates from cystic fibrosis patients"],"prefix":"10.1016","volume":"94","author":[{"given":"Giovanni","family":"Gherardi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulia","family":"Linardos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arianna","family":"Pompilio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ersilia","family":"Fiscarelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5850-2810","authenticated-orcid":false,"given":"Giovanni","family":"Di Bonaventura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.diagmicrobio.2019.01.012_bb0005","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1001\/archinte.1985.00360090089015","article-title":"Pseudomonas bacteremia. Retrospective analysis of 410 episodes","volume":"145","author":"Bodey","year":"1985","journal-title":"Arch Intern Med"},{"issue":"10","key":"10.1016\/j.diagmicrobio.2019.01.012_bb0010","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.ajic.2018.03.013","article-title":"Clinical epidemiology of carbapenem-resistant gram-negative sepsis among hospitalized patients: shifting burden of disease?","volume":"46","author":"Britt","year":"2018","journal-title":"Am J Infect Control"},{"key":"10.1016\/j.diagmicrobio.2019.01.012_bb0015","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1093\/jac\/dku048","article-title":"Epidemiology and carbapenem resistance mechanisms of carbapenem non-susceptible Pseudomonas aeruginosa collected during 2009-2011 in 14 European and Mediterranean countries","volume":"69","author":"Castanheira","year":"2014","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"10.1016\/j.diagmicrobio.2019.01.012_bb0020","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1378\/chest.07-0005","article-title":"Different bacteriology and prognosis of thoracic empyemas between patients with chronic and end-stage renal disease","volume":"132","author":"Chen","year":"2007","journal-title":"Chest"},{"key":"10.1016\/j.diagmicrobio.2019.01.012_bb0025","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1513\/AnnalsATS.201402-050AS","article-title":"Antibiotic management of lung infections in cystic fibrosis. I. The microbiome, methicillin-resistant Staphylococcus aureus, gram-negative bacteria, and multiple infections","volume":"11","author":"Chmiel","year":"2014","journal-title":"Ann Am Thorac Soc"},{"issue":"1","key":"10.1016\/j.diagmicrobio.2019.01.012_bb0030","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s40121-016-0141-y","article-title":"In vitro activity of ceftolozane\/tazobactam alone or with an aminoglycoside against multi-drug-resistant Pseudomonas aeruginosa from pediatric cystic fibrosis patients","volume":"6","author":"Dassner","year":"2017","journal-title":"Infect Dis Ther"},{"issue":"1","key":"10.1016\/j.diagmicrobio.2019.01.012_bb0035","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.diagmicrobio.2018.05.002","article-title":"Ceftolozane\/tazobactam sensitivity patterns in Pseudomonas aeruginosa isolates recovered from sputum of cystic fibrosis patients","volume":"92","author":"Finklea","year":"2018","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"9","key":"10.1016\/j.diagmicrobio.2019.01.012_bb0040","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1164\/rccm.200812-1845PP","article-title":"Clinical practice guidelines for pulmonary therapies committee. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations","volume":"180","author":"Flume","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"issue":"10","key":"10.1016\/j.diagmicrobio.2019.01.012_bb0045","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1056\/NEJM199409083311003","article-title":"Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group","volume":"331","author":"Fuchs","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diagmicrobio.2019.01.012_bb0050","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1093\/jac\/49.2.229","article-title":"Prescribing guidelines for severe Pseudomonas infections","volume":"49","author":"Giamarellou","year":"2002","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"10.1016\/j.diagmicrobio.2019.01.012_bb0055","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02696-16","article-title":"Importance of the exopolysaccharide matrix in antimicrobial tolerance of Pseudomonas aeruginosa aggregates","volume":"61","author":"Goltermann","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2019.01.012_bb0060","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.jcf.2012.02.006","article-title":"Results of antibiotic susceptibility testing do not influence clinical outcome in children with cystic fibrosis","volume":"11","author":"Hurley","year":"2012","journal-title":"J Cyst Fibros"},{"issue":"1","key":"10.1016\/j.diagmicrobio.2019.01.012_bb0065","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.diagmicrobio.2015.04.012","article-title":"Microbiological activity of ceftolozane\/tazobactam, ceftazidime, meropenem, and piperacillin\/tazobactam against Pseudomonas aeruginosa isolated from children with cystic fibrosis","volume":"83","author":"Kuti","year":"2015","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2019.01.012_bb0070","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1004083","article-title":"Cationic antimicrobial peptides promote microbial mutagenesis and pathoadaptation in chronic infections","volume":"10","author":"Limoli","year":"2014","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.diagmicrobio.2019.01.012_bb0075","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1128\/CMR.00040-09","article-title":"Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms","volume":"22","author":"Lister","year":"2009","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.diagmicrobio.2019.01.012_bb0080","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.ijantimicag.2009.03.021","article-title":"Activity of cephalosporin CXA-101 (FR264205) against Pseudomonas aeruginosa and Burkholderia cepacia group strains and isolates","volume":"34","author":"Livermore","year":"2009","journal-title":"Int J Antimicrob Agents"},{"issue":"8","key":"10.1016\/j.diagmicrobio.2019.01.012_bb0085","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1093\/jac\/dkt115","article-title":"Diversity of \u03b2-lactam resistance mechanisms in cystic fibrosis isolates of Pseudomonas aeruginosa: a French multicentre study","volume":"68","author":"Llanes","year":"2013","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"10.1016\/j.diagmicrobio.2019.01.012_bb0090","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","article-title":"Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance","volume":"18","author":"Magiorakos","year":"2012","journal-title":"Clin Microbiol Infect"},{"issue":"11","key":"10.1016\/j.diagmicrobio.2019.01.012_bb0095","doi-asserted-by":"crossref","first-page":"6735","DOI":"10.1128\/AAC.01046-16","article-title":"Antimicrobial susceptibility of Pseudomonas aeruginosa isolated from cystic fibrosis patients in Northern Europe","volume":"60","author":"Mustafa","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2019.01.012_bb0100","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3389\/fmicb.2011.00065","article-title":"Pseudomonas aeruginosa: resistance to the max","volume":"2","author":"Poole","year":"2011","journal-title":"Front Microbiol"},{"issue":"4","key":"10.1016\/j.diagmicrobio.2019.01.012_bb0105","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s40121-017-0176-8","article-title":"Time-kill analysis of ceftolozane\/tazobactam efficacy against mucoid Pseudomonas aeruginosa strains from cystic fibrosis patients","volume":"6","author":"Rac","year":"2017","journal-title":"Infect Dis Ther"},{"issue":"7","key":"10.1016\/j.diagmicrobio.2019.01.012_bb0110","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00465-17","article-title":"Ceftolozane-tazobactam activity against Pseudomonas aeruginosa clinical isolates from U.S. hospitals: report from the PACTS antimicrobial surveillance program, 2012 to 2015","volume":"61","author":"Shortridge","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.diagmicrobio.2019.01.012_bb0115","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/resp.12714","article-title":"Pseudomonas aeruginosa antibiotic resistance in Australian cystic fibrosis centres","volume":"21","author":"Smith","year":"2016","journal-title":"Respirology"},{"key":"10.1016\/j.diagmicrobio.2019.01.012_bb0120","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1093\/cid\/ciw243","article-title":"Ceftazidime\/avibactam and ceftolozane\/ tazobactam: second-generation beta-lactam\/beta-lactamase inhibitor combinations","volume":"63","author":"van Duin","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"10","key":"10.1016\/j.diagmicrobio.2019.01.012_bb0125","doi-asserted-by":"crossref","first-page":"e154","DOI":"10.1002\/phar.1825","article-title":"Successful use of ceftolozane-tazobactam to treat a pulmonary exacerbation of cystic fibrosis caused by multidrug-resistant Pseudomonas aeruginosa","volume":"36","author":"Vickery","year":"2016","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.diagmicrobio.2019.01.012_bb0130","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.cmi.2017.09.001","article-title":"New agents for the treatment of infections with Gram-negative bacteria: restoring the miracle or false dawn?","volume":"23","author":"Wright","year":"2017","journal-title":"Clin Microbiol Infect"},{"issue":"9","key":"10.1016\/j.diagmicrobio.2019.01.012_bb0135","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1111\/j.1469-0691.2010.03130.x","article-title":"Activity of the new cephalosporin CXA-101 (FR264205) against Pseudomonas aeruginosa isolates from chronically-infected cystic fibrosis patients","volume":"16","author":"Zamorano","year":"2010","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.diagmicrobio.2019.01.012_bb0140","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s40265-013-0168-2","article-title":"Ceftolozane\/tazobactam: a novel cephalosporin\/ beta-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli","volume":"74","author":"Zhanel","year":"2014","journal-title":"Drugs"}],"container-title":["Diagnostic Microbiology and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889318306400?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889318306400?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,25]],"date-time":"2019-10-25T02:14:42Z","timestamp":1571969682000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0732889318306400"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["S0732889318306400"],"URL":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2019.01.012","relation":{},"ISSN":["0732-8893"],"issn-type":[{"type":"print","value":"0732-8893"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of in vitro activity of ceftolozane-tazobactam compared to other antimicrobial agents against Pseudomonas aeruginosa isolates from cystic fibrosis patients","name":"articletitle","label":"Article Title"},{"value":"Diagnostic Microbiology and Infectious Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2019.01.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}